Video 1 min read

Lyme Disease: could an mRNA vaccine be a game-changer?

Published the Updated By Sacha Tembe and Jeanne Fenouil; Translation: AI-assisted

What if mRNA technology could finally offer protection against Lyme disease? At the Institut Pasteur, Valérie Choumet and her team have achieved promising results: a vaccine candidate that, in a preclinical model, completely prevented the transmission of the bacterium following a tick bite.
  • #Ticks
  • #Lyme disease
  • #Vaccines
Vaccin contre Lyme

Pour visionner cette vidéo, vous devez accepter le cookie YouTube.

© Script: Jeanne Fenouil and Sacha Tembe - Filmmaking: Jeanne Fenouil (video in french, english subtitles available translated by AI)

 

Lyme borreliosis: messenger RNA, a promising new vaccine lead?

Valérie Choumet and her team at the Institut Pasteur have obtained promising results for a new candidate vaccine against Lyme disease.

Using messenger RNA technology - already proven for other infectious diseases - this vaccine targets the OspA protein present on the surface of the Borrelia burgdorferi bacterium responsible for this infection.

Encouraging results:

  • Enhanced immune response: significantly higher antibody levels were observed in the animal model, compared with those generated by traditional protein vaccines
  • Complete protection: the vaccine completely prevented transmission of the bacterium when bitten by a tick in the preclinical model used

With the increasing incidence of this disease in the northern hemisphere, these results pave the way for a new, potentially more effective and sustainable prevention strategy.